On the other hand, in chimeric antigen receptor (CAR) T cell treatment for cancer, integration of the lentiviral CAR cassette into specific cancer genes can potentiate CAR-T cell therapeutic effect by promoting the persistence of CAR T cells (by insertional activation of BACH2) (42) or driving proliferation of specific clones (by insertional disruption of TET2 or insertional activation of VAV1) (56, 57). Here, BACH2 is linked to cancer.